QURE250516P21000
- 7.30
- 0.000.00%
uniQure NV Newsroom
Leerink Partners Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $48
Express News | Uniqure NV : Leerink Partners Raises Target Price to $48 From $44
Gene Therapy Developers Rise on Comments From FDA's Makary
Express News | HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $70 Price Target
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Sector Update: Health Care Stocks Decline Late Afternoon
$QURE Stock Is up 40% Today. Here's What We See in Our Data.
UniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Why Is Gene Therapy Developer UniQure Stock Trading Higher On Thursday?
UniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $30
Chardan Capital Initiates UniQure NV(QURE.US) With Buy Rating, Announces Target Price $38
UniQure Price Target Raised to $38.00/Share From $27.00 by Chardan Capital
UniQure Is Maintained at Buy by Chardan Capital
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating
Uniqure Insider Sold Shares Worth $291,629, According to a Recent SEC Filing
Insider Sale: Chief Medical Officer of $QURE Sells 1,350 Shares
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $30
Stifel Nicolaus Sticks to Their Buy Rating for UniQure (QURE)